Kymera Therapeutics (KYMR) Income towards Parent Company (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Income towards Parent Company data on file, last reported at -$494.8 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 151.9% year-over-year to -$494.8 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 90.29% decrease from a year earlier, with the FY2025 full-year figure at -$749.9 million, down 50.63% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$494.8 million, down from -$97.9 million in the prior quarter.
• Over the last five years, Income towards Parent Company for KYMR reached as high as -$38.7 million in Q4 2022 and fell as low as -$494.8 million in Q1 2026.
• Historically, Income towards Parent Company has averaged -$175.5 million across 5 years, with a median of -$168.5 million in 2022.
• Across the five-year window, Income towards Parent Company jumped 65.08% in 2022 and slumped 369.66% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$38.7 million in 2022, then slumped by 369.66% to -$181.7 million in 2023, then soared by 55.54% to -$80.8 million in 2024, then retreated by 21.2% to -$97.9 million in 2025, then tumbled by 405.39% to -$494.8 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$494.8 million in Q1 2026, -$97.9 million in Q4 2025, and -$342.6 million in Q3 2025.